Trodelvy (sacituzumab govitecan) is a medication used for certain breast cancers and bladder cancers when other treatments stop working. It’s given as an infusion through the vein once a week for 2 weeks (on Day 1 and Day 8) in each 21-day treatment cycle. You’ll need regular blood tests to make sure that your white blood cell counts don’t drop too low. Other common side effects of Trodelvy (sacituzumab govitecan) include hair loss, fatigue, and serious diarrhea.
Advanced or metastatic breast cancer:
Triple-negative breast cancer, after at least 2 previous treatments stop working
HER2-negative breast cancer, after hormone therapy and at least 2 previous treatments stop working
Advanced or metastatic bladder cancer, after certain treatments stop working
Trodelvy (sacituzumab govitecan) is a type of antibody-drug conjugate that’s made up of 2 parts: an antibody that targets a protein in the body called Trop-2 and an anticancer medication called SN-38.
In certain cancers, tumor cells have more of the Trop-2 protein compared to normal cells. The antibody part of Trodelvy (sacituzumab govitecan) attaches to the Trop-2 protein on cancer cells to get inside. Once inside, the anticancer part SN-38 damages the tumor cell’s DNA. This stops cancer cells from growing and spreading.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Recommended treatment option for certain breast and bladder cancers, after previous treatments stop working
Targeted therapy that works in a more specific way than traditional chemotherapy
Oncologist can adjust the dose if you experience certain side effects
Commonly causes diarrhea, nausea, and vomiting
Can cause low white blood cells, which can raise risk for infections
Infusions can take a few hours
You’ll receive medications to prevent infusion reactions before each Trodelvy (sacituzumab govitecan) treatment. If you feel chest pain, dizziness, trouble breathing, itching, or hives, tell your treatment team. They will pause the infusion, check your symptoms, and give you extra medications if needed. Once you feel better, they might restart the infusion at a slower rate.
Your first Trodelvy (sacituzumab govitecan) infusion will take 3 hours. If it goes smoothly, future infusions will take 1 to 2 hours. After each infusion, you’ll likely have to remain in the treatment center for about 30 minutes to make sure you aren’t having any other reactions.
Trodelvy (sacituzumab govitecan) often causes nausea and vomiting. Before each dose, you’ll receive medications to prevent these symptoms. Your oncologist will also likely prescribe medications for you to take at home as needed. If you still have trouble with nausea and vomiting, let your treatment team know.
Trodelvy (sacituzumab govitecan) shouldn’t be taken in pregnancy since it can harm unborn babies. If you can become pregnant, use effective birth control while taking Trodelvy (sacituzumab govitecan) and for 6 months after your last dose. If you’re male and have a partner who can become pregnant, use birth control throughout treatment and for 3 months after your last dose.
Trodelvy (sacituzumab govitecan) might affect fertility. Talk with your oncology team if you’re planning on becoming pregnant before starting Trodelvy (sacituzumab govitecan).
Avoid breastfeeding during treatment and for 1 month after the last dose of Trodelvy (sacituzumab govitecan) since it isn’t known if the medication can affect your baby.
Trodelvy (sacituzumab govitecan) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Trodelvy (sacituzumab govitecan) affects your bone marrow and causes your body to make fewer white blood cells. Low amounts of white blood cells can raise your chance of bleeding and make you more likely to get infections. You’ll have your blood drawn during treatment with Trodelvy (sacituzumab govitecan) to make sure the medication is safe to take. If your white blood cell levels are too low, your oncologist might lower your dose, adjust your treatment schedule, or prescribe extra medications to boost your white blood cells. Talk to your oncologist right away if you develop a fever or other signs of infection, like sore throat, cough, trouble catching your breath, chills, or pain or burning on urination.
Diarrhea is a common Trodelvy (sacituzumab govitecan) side effect. Although the diarrhea is usually mild, some people taking the medication experience severe diarrhea, which can lead to dehydration and kidney problems. Talk to your oncologist if you experience diarrhea, they might recommend over-the-counter diarrhea medications, like loperamide (Imodium A-D), to help with your symptoms. Stay hydrated and let your doctor know if you have black or bloody stools, signs of dehydration (e.g. dizziness, lightheadedness), diarrhea lasting more than 24 hours, or diarrhea that’s interfering with your ability to eat and drink as usual.
Infusion reactions can happen with Trodelvy (sacituzumab govitecan), and your treatment team will give you medications (e.g. acetaminophen (Tylenol), diphenhydramine (Benadryl), famotidine (Pepcid AC)) to prevent these reactions. But in rare cases, people with severe infusion reactions had to go to the hospital and receive urgent treatment. Notify your treatment team if you have shortness of breath, chills, flushing, chest discomfort, swelling, itching, nausea, or vomiting during the infusion. They’ll likely pause the infusion and give you medications to manage your symptoms. If the reaction isn’t serious, they’ll continue the Trodelvy (sacituzumab govitecan) infusion at a slower rate. After each infusion, the team will monitor you for at least 30 minutes to make sure there aren’t any reactions.
Many people taking Trodelvy (sacituzumab govitecan) have nausea and vomiting. Nausea can last for several days after you take your dose. Before each infusion, you’ll receive medication to prevent nausea and vomiting. Your oncologist might also prescribe other medications to take at home as needed. If you have nausea and the medications you have aren’t working well to manage it, let your healthcare team know. If your symptoms are severe, you might have to pause or stop taking Trodelvy (sacituzumab govitecan).
Risk factors: UGT1A128 mutation (change)
In studies, people who had certain changes in the gene UGT1A1 had higher rates of side effects with Trodelvy (sacituzumab govitecan). Specifically, people with these gene changes had low white blood counts earlier after treatment, and at higher rates. Your oncologist probably won’t test you for these gene changes before starting treatment, so it’s important to tell your treatment team if you’ve been told that you have changes in the UGT1A1 gene. If you do, your oncologist will likely keep a close eye on how you’re doing or make changes to your treatment plan.
Trodelvy (sacituzumab govitecan) can harm the unborn baby. If you’re able to have children, your oncologist will ask you to do a pregnancy test before starting treatment. Use birth control if you are taking the medication, and continue using birth control until 6 months after stopping the medication. Alert your healthcare team right away if you become pregnant while taking Trodelvy (sacituzumab govitecan). If you’re male and have a partner who could become pregnant, use birth control throughout treatment and for 3 months after your last dose.
The dose of Trodelvy (sacituzumab govitecan) is based on your weight.
Typically, you’ll receive 10 mg/kg as an infusion through the vein on days 1 and 8 of each 21-day treatment cycle.
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Bardia, A., et al. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. The New England Journal of Medicine.
Gilead Sciences. (2024). Trodelvy- sacituzumab govitecan powder, for solution [package insert]. DailyMed.
MedlinePlus. (2012). UGT1A1 gene.
National Cancer Institute. (2022). Hormone therapy for breast cancer.
National Cancer Institute. (2022). What is bladder cancer?
National Comprehensive Cancer Network. (2023). Bladder cancer.
National Comprehensive Cancer Network. (2024). Metastatic breast cancer.
Ramesh, M., et al. (2010). Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomedical Chromatography.
Rugo, H. S., et al. (2022). Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Journal of Clinical Oncology.
Shvartsur, A., et al. (2015). Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes & Cancer.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.